Fig. 2 |. TRMs localize in close proximity to tumour cells after seeding and enhance their antigen presentation and tissue remodelling programs in response to tumour cues.

a, Frequency of scRNA-seq groups in lungs from naive and tumour-bearing mice (left, n = 4 experiments with two pooled naive and two pooled tumour-bearing mice per experiment) and in human NSCLC tumours and adjacent non-involved lung tissue (right, 19 paired non-involved and tumour). The cell-type frequencies observed in the scRNA-seq mouse samples were proportionally weighted according to the labelling frequencies determined from fluorescence-activated cell sorting (FACS). Unpaired two-tailed t-test. NS, not significant. Data are mean ± s.e.m. b, Longitudinal analysis in an orthotopic mouse model of NSCLC (left). Graph (middle) shows tumour growth over time, and images (right) show tumour foci stained with haematoxylin and eosin (n = 3 day 5; n = 4 day 10; n= 4 day 15; n = 3 day 25; n = 8 day 30). Scale bar, 10 mm. c, Left, confocal imaging of tumour lesions (KP, green) and TRMs (MRC1, red) at different time points after the injection of KP cells. Scale bar, 50 μm (main images, day 5, 10 and 15); 100 μm (main images, days 25 and 30); 10 μm (insets). Right, quantification of the distribution of TRMs in advanced tumour lesions (day 30; n = 4 mice, 10 tumours). Unpaired two-tailed t-test; *P < 0.05. Data are mean ± s.e.m.